Jiangzhong Pharma Reports Mixed H1 2024 Results
Company Announcements

Jiangzhong Pharma Reports Mixed H1 2024 Results

China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.

China Resources Pharmaceutical Group Ltd. has announced that its subsidiary, Jiangzhong Pharmaceutical, has released its financial results for the first half of 2024, reporting an 8.66% increase in net profit attributable to shareholders despite an 8.02% decrease in revenue. The company’s total assets and net assets saw a marginal increase, while net cash flow from operating activities declined by 11.99%. These mixed results highlight the company’s profitability in a challenging period, with an improved net profit margin and basic earnings per share rising to 0.78 RMB.

For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskChina Resources Pharmaceutical Completes Green Cross HK Acquisition
TipRanks HongKong Auto-Generated NewsdeskChina Resources Subsidiary Reports Revenue Surge Amid Cash Challenges
TipRanks HongKong Auto-Generated NewsdeskChina Resources Sanjiu Reports Rising Profits Despite Cash Decline
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App